Congress has long had an interest in stemming the online sale of illegal opioids but investigating and identifying criminals who traffic these drugs on the dark web is incredibly challenging for law enforcement agencies. Enter the Dark Web Interdiction Act of 2022 (HR 7300, S 3782), a new bipartisan bill that seeks to improve the […]
Read More ›
With the release of the White House’s next phase National COVID-19 Preparedness Plan and looming deadlines to fund the federal government, including replenishing aid for pandemic relief, it has been an eventful month on Capitol Hill for the health care industry. In the most recent iteration of President Joseph R. Biden’s pandemic preparedness plan, the White House […]
Read More ›
The coronavirus disease 2019 pandemic prompted state and federal government to shift guidance and relax policies on a wide range of telehealth services, which resulted in a boom in remote offerings for patients. However, long before this rapid transformation in telehealth, telepharmacy, an increasingly popular form of remote pharmacy care, has operated under a patchwork of state laws with […]
Read More ›
Before DEA published an interim final rule in 2010, which gave practitioners the option to write prescriptions for controlled substances (CS) electronically, e-prescribing for CS was prohibited in many states. Now, 11 years later, the regulatory and technological landscape has shifted significantly. As part of the larger effort to curb the opioid crisis, many states […]
Read More ›
As has been reported extensively over the last several months, policymakers on both sides of the aisle have been unwavering in their pursuit to hold tech companies and social media platforms accountable for building a safer internet. Until recently, their focus has predominantly been on online platforms that serve as publishers of third-party content, such […]
Read More ›
After rampant sales of counterfeit masks, coronavirus disease 2019 (COVID-19) testing kits, medicines, and other goods over the past two years, there has been increased attention in Washington this holiday season on the health and safety risks of counterfeit products, particularly those sold online. Just before Black Friday, the United States Chamber of Commerce and US Customs and Border Protection launched […]
Read More ›
On September 27, 2021, for the first time in six years, Drug Enforcement Administration (DEA) issued a public safety alert warning Americans of a surge in deadly counterfeit pills containing fentanyl and methamphetamine flooding into the United States. The last time DEA issued a similar alert was to raise awareness of a national rise in […]
Read More ›
Cyberattacks targeting the nation’s critical infrastructure have become increasingly prevalent over the last few years, but, during the coronavirus disease 2019 (COVID-19) pandemic, attacks across all sectors have rapidly accelerated. Greater emphasis on remote work and business operations have created the “perfect storm” for cybercriminals to exploit security flaws within many organizations, especially the health […]
Read More ›
Earlier this month, FDA announced it will provide states one more year to decide whether to sign its compounding memorandum of understanding (MOU) before the agency begins enforcing the statutory 5% limit on out-of-state distribution of compounded human drug products. This comes after many states asked for more time to wrangle with the legal and […]
Read More ›
Prescription drug prices continue soaring and no light is visible at the end of the tunnel. Wanting to bring relief to cash-strapped constituents, many states are creating their own drug importation programs from Canada using an FDA rule finalized in November 2020. Regulating these systems will be complex, but states do not have to go it alone. That’s why I’m focusing my term as NABP President on helping them navigate the process to ensure the integrity of the drug […]
Read More ›